Facioscapulohumeral Muscular Dystrophy Clinical Trial
— FSHDOfficial title:
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophy
Verified date | December 2023 |
Source | aTyr Pharma, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
ATYR1940-C-006 is a multi-national, multicenter study being conducted at centers in the United States (US) and Europe who participated in Study ATYR1940-C-003 (Stage 1 only) or Study ATYR1940-C-004 (that is, the parent studies).
Status | Completed |
Enrollment | 8 |
Est. completion date | April 18, 2017 |
Est. primary completion date | April 18, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 25 Years |
Eligibility | Inclusion Criteria: 1. Enrolled in and completed the treatment period in the parent study. 2. Demonstrated, in the Sponsor's and Investigator's opinions, acceptable tolerability of ATYR1940. 3. In the Investigator's opinion, participant has shown acceptable compliance with ATYR1940 and the study procedures in the parent study and is willing and able to comply with all procedures in the current study. 4. Is, in the opinion of the Investigator and Sponsor, a suitable candidate for continued ATYR1940 treatment. 5. Provide written informed consent or assent after the nature of the study has been explained and prior to the performance of any research-related procedures. Exclusion Criteria: 1. Is expected to require treatment with curcumin or systemic albuterol (intermittent inhaled albuterol is permissible) during study participation; or use of a product that putatively enhances muscle growth (for example, insulin-like growth factor, growth hormone) or activity (for example, Coenzyme Q, Coenzyme A, creatine, L-carnitine) on a chronic basis; or statin treatment initiation or significant adjustment to statin regimen (stable, chronic statin use is permissible). 2. Planned to receive any vaccination during study participation. 3. Abnormal baseline findings, medical condition(s), or laboratory findings that, in the Investigator's opinion, might jeopardize the participant's safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study. 4. Evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, dermatological, or gastrointestinal disease, or has a condition that requires immediate surgical intervention, other treatment, or may not allow safe participation. 5. If female and of childbearing potential (premenopausal and not surgically sterile), has a positive pregnancy test at entry or is unwilling to use contraception from the time of entry through the 3-month Follow-up visit. Acceptable methods of birth control include abstinence, barrier methods, hormones, or intra-uterine device. 6. If male, is unwilling to use a condom plus spermicide during sexual intercourse from the time of entry through the 1 month Follow-up visit. |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet, University of Copenhagen | Copenhagen | |
Italy | Foundation IRCCS Neurological Institute Carlo | Milan | |
United States | University of California, Irvine, ALS and Neuromuscular Center | Irvine | California |
United States | University of Utah | Salt Lake City | Utah |
United States | Stanford University | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
aTyr Pharma, Inc. |
United States, Denmark, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs were defined as adverse events (AEs) with an onset following administration of the first dose of study drug. AEs were defined as any untoward medical occurrence in a participant administered study drug and that does not necessarily have a causal relationship with the study drug. Worsening of a pre-existing medical condition should have been considered an AE if there was either an increase in severity, frequency, or duration of the condition or an association with significantly worse outcomes. SAEs were defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section. | Up to End of Study (up to approximately Week 39) | |
Primary | Number of Participants With Positive Anti-Drug Antibodies (ADA) | Summarized titers are reported below. | Up to End of Study (up to approximately Week 39) | |
Primary | Number of Participants With a Jo-1 Antibody (Ab) Test Result =1.5 Units/Milliliter (U/mL) | Participants with Jo-1 Ab levels =1.5 U/mL were to be discontinued from dosing of the study drug. | Up to End of Study (up to approximately Week 39) | |
Primary | Number of Participants With a Clinical Laboratory Abnormality Leading to an AE | Laboratory parameters included hematology (hematocrit, hemoglobin, red blood cell count, white blood cell count neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelet count); serum chemistries (blood urea nitrogen, creatinine, total bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, total protein, sodium, potassium, bicarbonate, calcium, chloride, magnesium, inorganic phosphate, creatine kinase, lactate dehydrogenase, C-reactive protein, troponin, myoglobin, insulin-like growth factor 1, and cholesterol [nonfasting]); and urinalysis (color, pH, specific gravity, protein, glucose, ketones, and blood). Clinically significant laboratory abnormalities were based upon Investigator's discretion. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. | Up to End of Study (up to approximately Week 39) | |
Primary | Number of Participants With a Clinically Significant Pulmonary Function Event Resulting in a TEAE | Pulmonary evaluations included pulmonary function tests and pulse oximetry. Clinically significant changes were to be reported as adverse events. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. | Up to End of Study (up to approximately Week 39) | |
Primary | Number of Participants With a Clinically Significant Electrocardiogram (ECG) Abnormality Leading to a TEAE | ECG parameters that were evaluated included heart rate and PR, QR, and QT intervals. A clinically significant ECG abnormality was based upon the Investigator's discretion. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. | Up to End of Study (up to approximately Week 39) | |
Primary | Number of Participants With Vital Sign Abnormality Resulting in a TEAE | The vital sign parameters that were evaluated included heart rate, systolic and diastolic blood pressure, and respiration rate as well as temperature. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. | Up to End of Study (up to approximately Week 39) | |
Primary | Change From Baseline in Manual Muscle Testing (MMT) Score at Week 12 | MMT (muscle strength) will be graded using a modified Medical Research Council scale. Scores were converted to 13-point scale (range from 0 [on contraction palpable] to 12 [normal strength]). An overall total score was calculated by summing all scores for a total possible score of 336. Decreased muscle strength was indicated by a decreased score. An overall total score was calculated as long as 24 of the 28 individual scores were non-missing. | Baseline, Week 12 | |
Secondary | Change From Baseline in Creatinine Kinase at Week 12 | Baseline, Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00082108 -
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
|
||
Completed |
NCT02579239 -
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 1/Phase 2 | |
Terminated |
NCT02927080 -
Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 2 | |
Completed |
NCT02625662 -
Facioscapulohumeral Dystrophy in Children
|
||
Recruiting |
NCT04001582 -
The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry
|
||
Recruiting |
NCT06425445 -
Quantitative Assessment of Orofacial Muscle Function in FSHD
|
N/A | |
Terminated |
NCT03943290 -
Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
|
Phase 2 | |
Completed |
NCT01596803 -
Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD)
|
N/A | |
Active, not recruiting |
NCT03458832 -
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
|
||
Completed |
NCT02766985 -
Rasch-analysis of Clinical Severity in FSHD
|
||
Active, not recruiting |
NCT01671865 -
Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy
|
||
Completed |
NCT02413190 -
Bone Health in Facioscapulohumeral Muscular Dystrophy
|
||
Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
Completed |
NCT01437345 -
A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD
|
N/A | |
Not yet recruiting |
NCT06086548 -
Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics
|
||
Completed |
NCT00821548 -
Electrostimulation of Shoulder Girdle and Quadriceps Muscles in Facioscapulohumeral Muscular Dystrophy Patients
|
N/A | |
Completed |
NCT05178706 -
Effectiveness of Upper Extremity Rehabilitation in pwFSHD (Patient With Facioscapulohumeral Dystrophia)
|
||
Completed |
NCT00104078 -
Study Evaluating MYO-029 in Adult Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05019625 -
Biomarker Development for Muscular Dystrophies
|
||
Completed |
NCT03123913 -
Study of Testosterone and rHGH in FSHD
|
Phase 1 |